A ten year longitudinal examination of the incidence rate and age of childhood encephalopathy diagnoses in an autism spectrum disorder diagnosed cohort

• Autorzy: Kern J.K. , Geier D.A. , Homme K.G. , Geier M.R.
• Języki publikacji: EN

Abstrakty

EN

Autism spectrum disorder (ASD) is defined by persistent deficits in social communication/interaction and stereotypic behaviors with many diagnosed persons experiencing a developmental regression at >1 year‑old. It was hypothesized that progressive childhood encephalopathy is an important etiological factor in ASD pathogenesis. This hypothesis‑testing study examined the relationship between diagnosed childhood encephalopathy and ASD. The Independent Healthcare Research Database is composed of de‑identified linked eligibility and claim healthcare records prospectively generated from the Florida Medicaid system. A cohort of 101,736 persons eligible for Florida Medicaid from 1990‑2009 and continuously eligible with ≥10 outpatient office visits during the 120 month period following birth were examined using SAS software. There were 1,397 persons (7,223 person‑years) in the ASD diagnosed cohort and 100,339 persons (980,786 person‑years) in the undiagnosed cohort. The incidence rate of encephalopathy was examined using Cox proportional hazards ratio models. In the ASD cohort relative to the undiagnosed cohort, a significantly increased incidence rate of diagnosed encephalopathy was observed in the unadjusted and adjusted models. The risk for an encephalopathy diagnosed at >1 year‑old was greater than for an encephalopathy diagnosed at <1 year‑old. This study provides important new evidence supporting the hypothesis that a significant number of children with an eventual ASD diagnosis experience a progressive childhood encephalopathy diagnosed at >1 year‑old.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2020
• Tom: 80
• Numer: 1
• Opis fizyczny: p.66-75,fig.,ref.

Twórcy

autor

Kern J.K.

• Institute of Chronic Illnesses, Inc, Silver Spring, MD, USA
• CoMeD, Inc, Silver Spring, MD, USA

autor

Geier D.A.

• Institute of Chronic Illnesses, Inc, Silver Spring, MD, USA
• CoMeD, Inc, Silver Spring, MD, USA

autor

Homme K.G.

• International Academy of Oral Medicine and Toxicology, Champions Gate, FL, USA

autor

Geier M.R.

• Institute of Chronic Illnesses, Inc, Silver Spring, MD, USA

Bibliografia

• AlSagob M, Colak D, Kaya N (2015) Genetics of autism spectrum disorder: an update on copy number variations leading to autism in the next gen‑ eration sequencing era. Discov Med 19: 367–379.
• American Psychiatric Association (2013) Diagnostic criteria for autistic disorder. In Diagnostic and Statistical Manual of Mental Disorders (5th edi‑ tion). Washington, DC, American Psychiatric Association. Badawi N, Dixon G, Felix JF, Keogh JM, Petterson B, Stanley FJ, Kurinczuk JJ (2006) Autism following a  history of newborn encephalopathy: more than a coincidence? Dev Med Child Neurol 48: 85–89.
• Bauman M, Filipek PA, Kemper TL (1997) Early infantile autism. In: Cerebellum and Cognition. Schmahmann JD (eds). San Diego: Academic Press, pp. 367–386.
• Bjorklund G, Saad K, Chirumbolo S, Kern JK, Geier DA, Geier MR, Urbina MA (2016) Immune dysfunction and neuroinflammation in autism spectrum disorder. Acta Neurobiol Exp 76: 257–268.
• Bjorklund G, Kern JK, Urina MA, Saad K, El‑Houfey AA, Geier DA, Chirumbolo S, Geier MR, Mehta JA, Aaseth J (2018) Cerebral hypoperfu‑ sion in autism spectrum disorder. Acta Neurobiol Exp 78: 21–29.
• Dheen ST, Kaur C, Ling EA (2007) Microglial activation and its implications in the brain diseases. Curr Med Chem 14: 1189–1197.
• Geier DA, Hooker BS, Kern JK, King PG, Sykes LK, Geier MR (2013) A two‑phase study evaluating the relationship between Thimerosal‑contain‑ ing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States. Transl Neurodegener 2: 25.
• Geier DA, Kern JK, Geier MR (2012) A prospective cross‑sectional cohort assessment of health, physical, and behavioral problems in autism spectrum disorders. Maedica 7: 193–200.
• Geier D, Kern J, Geier M (2018) Neonatal factors among subjects diagnosed with a pervasive developmental disorder in the US. J Matern Fetal Neo‑ ntal Med 31: 1709–1714.
• Geier DA, Kern JK, Sykes LK, Geier MR (2016) Examining genotypic variation in autism spectrum disorder and its relationship to parental age and phenotype. Appl Clin Genet 9: 121–129.
• Kern JK, Geier DA, Audhya T, King PG, Sykes LK, Geier MR (2012) Evidence of parallels between mercury intoxication and the brain pathology in autism. Acta Neurobiol Exp 72: 113–153.
• Kern JK, Geier DA, Geier MR (2014b) Evaluation of regression in autism spectrum disorder based on parental reports. N Am J Med Sci 6: 41–47.
• Kern JK, Geier DA, Homme KG, King PG, Bjorklund G, Chirumbolo S, Geier  MR (2017) Developmental neurotoxicants and the vulnerable male brain: a systematic review of suspected neurotoxicants that disproportionally affect males. Acta Neurobiol Exp 77: 269–296.
• Kern JK, Geier DA, King PG, Sykes LK, Mehta JA, Geier MR (2015) Shared brain connectivity issues, symptoms, and comorbidities in autism spectrum disorder, attention deficit/hyperactivity disorder, and Tourette syndrome. Brain Connect 5: 321–335.
• Kern JK, Geier DA, Sykes LK, Geier, MR (2013) Evidence of neurodegeneration in autism spectrum disorder. Transl Neurodegener 2: 17.
• Kern JK, Geier DA, Sykes LK, Homme KG, Geier MR (2014a) Medical condi‑ tions in autism and events associated with initial onset of autism. OA Autism 2: 9.
• Kern JK, Geier DA, Sykes LK, Geier MR (2016) Relevance of neuroinflamma‑ tion and encephalitis in autism. Front Cell Neurosci 9: 519.
• Kern JK, Jones AM (2006) Evidence of toxicity, oxidative stress, and neuro‑ nal insult in autism. J Toxicol Environ Health B Crit Rev 9: 485–499.
• Laurence JA, Fatemi SH (2005) Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects. Cerebellum 4: 206–210.
• Lull ME, Block ML (2010) Microglial activation and chronic neurodegeneration. Neurotherapeutics 7: 354–365.
• Ozonoff S, Gangi D, Hanzel EP, Hill A, Hilll MM, Miller M, Schwichtenberg AJ, Steinfield MB, Parikh C, Iosif AM (2018) Onset patterns in autism: variation across informants, methods, and timing. Autism Res 11: 788–797.
• Piore A. The Rogue Immune Cells That Wreck the Brain. MIT Technology Review. https://www.technologyreview.com/s/601137/the-rogue‑ ‑immune‑cells‑that‑wreck‑the‑brain/. Published 04/04/2016. Accessed 08/30/2018.
• Rodriguez JI, Kern JK (2011) Evidence of microglial activation in autism and its possible role in brain underconnectivity. Neuron Glia Biology 7: 205–213.
• Schonwald A, Robbins M, Hisama F, Wolff R, Becker R, Nasir R, Urion DK, Milunsky JM, Shen Y, Dies KA, Holm IA, Bridgemohan C, Sobeih MM, Caronna EB, Miller KJ, Frazier JA, Silverstein I, Picker J, Weissman  L, Raffalli P, Jeste S, Demmer LA, Peters HK, Brewster SJ, Kowalczyk SJ, Rosen‑Sheidley B, McGowan C, Duda AW 3rd, Lincoln SA, Lowe KR, Rappaport L, Gusella JF, Walsh CA, Wu BL, Miller DT; Autism Consortium Clinical Genetics/DNA Diagnostics Collaboration (2010) Clinical genetic testing for patients with autism spectrum disorders. Pediatrics 125: e727–e735.
• Werner E, Dawson G (2005) Validation of the phenomenon of autistic regression using home videotapes. Arch Gen Psychiatry 62: 889–895.
• Zindler E, Zipp F (2010) Neuronal injury in chronic CNS inflammation. Best Pract Res Clin Anaesthesiol 24: 551–562.

Identyfikatory

DOI

10.21307/ane-2020-007